## Guide to referring for Whole Genome Sequencing (WGS) for Solid Tumours

## Before referring:

- Check patient is eligible for WGS and select appropriate M code using the National genomic test directory for cancer <a href="https://www.england.nhs.uk/publication/national-genomic-test-directories/">https://www.england.nhs.uk/publication/national-genomic-test-directories/</a>
- Discuss patient feasibility and eligibility at MDT.

## **Referral Process:**

- 1. Fill in a Record of Discussion with the patient <a href="https://southeastgenomics.nhs.uk/wp-content/uploads/2021/04/GMS-WGS-RoD-Pilot-April-2021.pdf">https://southeastgenomics.nhs.uk/wp-content/uploads/2021/04/GMS-WGS-RoD-Pilot-April-2021.pdf</a>
  - o Information sheets available for patients here:
    - WGS <u>https://southeastgenomics.nhs.uk/wp-content/uploads/2020/12/Patient\_Information\_Cancer\_v2.2.pdf</u>
    - National Genomic Research Library: <u>https://southeastgenomics.nhs.uk/wp-content/uploads/2020/12/Patient\_Information\_Research\_V1.3.pdf</u>
- 2. Complete interventional radiology / surgery request with specific request for tissue to be **fresh frozen**, and not to be placed in formalin.
- 3. Request an EDTA blood sample.
- 4. Member of the clinical team to complete sections highlighted in yellow on the Test Order Form (details below).
- 5. Member of the pathology team will sample tumour appropriately for WGS and snap-freeze (OCT, iso-pentane cooled in dry ice/ LN2 (store in freezer at -80C)). Frozen section slide reviewed by histopathology team to confirm tumour and tumour cellularity.
- 6. Member of the pathology team to complete sections highlighted in blue on the Test Order Form.
- 7. Completed Test Order Form and Record of Discussion emailed to <u>gst-tr.wgs@nhs.net</u> with CANCER WGS NHS Number: XXX XXX XXXX in the subject.
- 8. Frozen tissue, blood sample and TOF sent to Guy's Hospital (Synnovis Genetics Laboratory, 5th Floor Tower Wing, Guy's Hospital, London SE1 9RT) on dry ice and DNA Duty Tech Lead emailed to inform the sample is on its way: <u>DNADutyTechLead@viapath.co.uk</u>
  - a. The sample should ideally be sent with a morning courier, Monday-Thursday)

NHS Genomic Medicine Service, WGS Test Request Cancer, October 2022 v1.19 to be used for WGS go-live. This document is subject to version control and is regularly updated. Please confirm you are using the current version by contacting your local Genomic Laboratory Hub

	57	Genomic Laboratory Hub				
Genomic Medicine Service Whole Genome Sequencing (WGS) Test Request PLEASE DO NOT USE FOR NON-WGS TESTS		CANCER		IHS	· · ·	esting abora
<b>Requesting organis</b>	ation:					
GLH laboratory to r	receive sample:	Test Required			Provi	ding e
		Whole Genome Sequencin		ienome Sequencing		e wide
Patient first name		Ethnicity		•		pretati
Patient last name Date of birth (dd/mm/yyy) Hospital number		Test Directory Clinical Indication & code (cancer type & sub-type) The clinical indications listed at the battom of the pick list under NEW INDICATIONS' are not live for all NHS GLHs. Please check with GLHs prior to ordering.		Pleas	e sele	
					need	furthe
Gender Male Fer	nale 🔲 Other	Presentation status			Ploas	e prov
Postcode		Additional clinical information (if required)				•
		E.g. previous tumours, molecular testing, and relevant treatment history with date(s)			inclu	ding ra
NHS number					previ	ous tu
Reason NHS Numbe	ar net available:					
	or NHS number (e.g. foreign national)				Impo	rtant t
Other (provide reaso	on]:				- · ·	rtant t
Solid tumour reque	ests only				no Nł	HS nur
Metastatic		E.g. site of metastasis (if metastatic), or unknown primary Tumour topography Tumour morphology			Plaas	e indi
🗆 Unknown	Date of this diagnosis (dd/mm/yyy)					
Lymphoma					Lymp	homa
Haemato-oncology	liquid tumour requests only				Histo	patho
AML ALL Other (please specify):		SIHMDS Lab ID	Date of th	is diagnosis (dd/mm/yyy)		-
Complete for tumo	ur samples (being sent to GLH I	DNA extraction lab)			Samn	le ID:
🛛 🗖 Fresh frozen tu	mour Bone marrow E	3lood (EDTA) 🛛 🔲 Other (pl	ease specif	y):	· ·	
		er to sample handling guidance) must be provided below		time:	when	
Sample ID	Collection date / time	% Malignant nuclei / blast		M/PB provide volume nucleated cell count	malig	nant n
ų			and	nucleated cell count	tissue	e samp
Complete for corm	line semples (heing sent to GL	DNA extraction (ab)				•
Complete for germline samples (being sent to GLH DNA extraction lab)           Blood (EDTA)         Saliva         Fibroblasts         Skin biopsy         Other (please specify):						sis.
Sample ID	Collection date / time	Sample volume if applicat	ole Cor	mments	Please	e add o
					Tieuse	2 444 4
Responsible consultant		Main contact (if different from responsible consultant)				
Name: Department address:		Name: Department address:			The 'r	espon
Department address:		Department autress.			repor	t shou
Phone:		Phone:				
Email:		Email:			detail	S.
	denotes the Denoted of Director					le contra de la co

Patient conversation taken place; Record of Discussion form to follow

Requesting organisation: **Your hospital** GLH laboratory to receive sample: **South East GLH** 

Providing ethnicity ensures that there is equity of access to genetic testing in the wider population and it also helps us to improve variant analysis and interpretation. Please select from the drop-down options.

Please select the appropriate M code using the drop-down options. If you need further guidance, please refer to the National Genomic Test Directory.

Please provide details of family history of cancer, details of any treatment including radiotherapy and previous chemotherapy, any concurrent or previous tumour

Important to include an NHS number as required for the WGS pipeline. If no NHS number is available a reason will need to be provided.

Please indicate whether the sample is: 'Primary, Metastatic, unknown, Lymphoma'. Please also indicate date of first diagnosis. **Histopathology Lab ID: this is based on patient and surgery** 

Sample ID: this is based on the particular block or sample. Collection date / time: when the tissue was removed. % Malignant nuclei / blasts: invasive malignant nuclei must account for at least 30% of the nuclei present in the tissue sample submitted for WGS. There should also be less than 20% necrosis.

Please add details of the germline sample (EDTA) if you have these details.

The 'responsible contact' should be filled in by the consultant who the report should be sent to, 'main contact' should have the histopathologist details.